For the quarter ending 2025-09-30, RXRX has $1,399,526K in assets. $352,578K in debts. $659,836K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 659,836 | 525,110 | 500,453 | 594,350 |
| Restricted cash | 3,136 | 3,106 | 3,075 | 3,045 |
| Other receivables | 21,910 | 21,606 | 46,124 | 49,166 |
| Prepaid data assets | 0 | 0 | 2,470 | - |
| Other current assets | 29,223 | 37,338 | 32,023 | 67,708 |
| Total current assets | 714,105 | 587,160 | 584,145 | 714,269 |
| Restricted cash, non-current | 4,173 | 5,629 | 5,629 | 5,629 |
| Property and equipment, net | 111,706 | 120,038 | 126,834 | 141,063 |
| Operating lease right-of-use assets | 47,812 | 50,324 | 53,186 | 65,877 |
| Financing lease right-of-use assets | 21,726 | 23,242 | 24,757 | 26,273 |
| Intangible assets, net | 322,344 | 341,319 | 335,790 | 335,855 |
| Goodwill | 162,042 | 164,270 | 158,112 | 148,873 |
| Deferred tax assets | 957 | 957 | 2,003 | 1,934 |
| Other assets, non-current | 14,661 | 9,416 | 14,778 | 8,825 |
| Total assets | 1,399,526 | 1,302,355 | 1,305,234 | 1,448,598 |
| Accounts payable | 13,935 | 19,314 | 25,086 | 21,613 |
| Accrued expenses and other liabilities | 53,102 | 64,280 | 56,804 | 81,872 |
| Accrued data liability | 20,258 | 20,258 | - | - |
| Unearned revenue | 47,364 | 39,690 | 39,651 | 61,767 |
| Operating lease liabilities | 11,525 | 11,732 | 11,853 | 13,795 |
| Notes payable and financing lease liabilities | 8,919 | 8,752 | 8,587 | 8,425 |
| Total current liabilities | 155,103 | 164,026 | 141,981 | 187,472 |
| Unearned revenue, non-current | 111,204 | 126,243 | 129,609 | 118,765 |
| Operating lease liabilities, non-current | 50,028 | 53,395 | 56,024 | 67,250 |
| Notes payable and financing lease liabilities, non-current | 11,902 | 14,196 | 16,446 | 19,022 |
| Deferred tax liabilities | 23,312 | 23,784 | 22,437 | 16,575 |
| Other liabilities, non-current | 1,029 | 1,565 | 4,790 | 4,732 |
| Total liabilities | 352,578 | 383,209 | 371,287 | 413,816 |
| Common stock, 0.00001 par value 2,000,000,000 shares (class a 1,989,032,117 and class b 10,967,883) authorized as of september30, 2025 and december31, 2024 491,800,501 shares (class a 485,213,547, class b 5,967,334 and exchangeable 619,620) and 396,802,394 shares (class a 389,547,223, class b 6,958,575 and exchangeable 296,596) issued and outstanding as of september30, 2025 and december31, 2024, respectively | 5 | 4 | 4 | 4 |
| Additional paid-in capital | 2,980,729 | 2,681,111 | 2,553,492 | 2,473,698 |
| Accumulated deficit | -1,967,879 | -1,805,589 | -1,633,694 | -1,431,283 |
| Accumulated other comprehensive income (loss) | 34,093 | 43,620 | 14,145 | -7,637 |
| Total stockholders equity | 1,046,948 | 919,146 | 933,947 | 1,034,782 |
| Total liabilities and stockholders equity | 1,399,526 | 1,302,355 | 1,305,234 | 1,448,598 |
RECURSION PHARMACEUTICALS, INC. (RXRX)
RECURSION PHARMACEUTICALS, INC. (RXRX)